nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—Protein Kinase Inhibitors—Vandetanib—thyroid cancer	0.318	1	CiPCiCtD
Afatinib—Vandetanib—thyroid cancer	0.31	1	CrCtD
Afatinib—Gefitinib—Vandetanib—thyroid cancer	0.144	1	CrCrCtD
Afatinib—EPHA6—Vandetanib—thyroid cancer	0.0287	0.169	CbGbCtD
Afatinib—BLK—Vandetanib—thyroid cancer	0.0287	0.169	CbGbCtD
Afatinib—EGFR—Vandetanib—thyroid cancer	0.0258	0.152	CbGbCtD
Afatinib—LCK—Vandetanib—thyroid cancer	0.0234	0.138	CbGbCtD
Afatinib—ABL1—Vandetanib—thyroid cancer	0.0186	0.11	CbGbCtD
Afatinib—HIPK4—Sorafenib—thyroid cancer	0.0173	0.102	CbGbCtD
Afatinib—EPHA6—Sorafenib—thyroid cancer	0.0173	0.102	CbGbCtD
Afatinib—ABCG2—Vandetanib—thyroid cancer	0.00425	0.0251	CbGbCtD
Afatinib—ABCG2—Sorafenib—thyroid cancer	0.00256	0.0151	CbGbCtD
Afatinib—ABCG2—Doxorubicin—thyroid cancer	0.00156	0.00917	CbGbCtD
Afatinib—ABCB1—Sorafenib—thyroid cancer	0.000925	0.00545	CbGbCtD
Afatinib—Disease progression—Sorafenib—thyroid cancer	0.000908	0.0408	CcSEcCtD
Afatinib—Dermatitis acneiform—Vandetanib—thyroid cancer	0.00086	0.0387	CcSEcCtD
Afatinib—Blood potassium decreased—Vandetanib—thyroid cancer	0.000773	0.0347	CcSEcCtD
Afatinib—ERBB2—neck—thyroid cancer	0.000728	0.0833	CbGeAlD
Afatinib—Vandetanib—RET—thyroid cancer	0.000682	1	CrCbGaD
Afatinib—Ventricular dysfunction—Epirubicin—thyroid cancer	0.000635	0.0286	CcSEcCtD
Afatinib—Ventricular dysfunction—Doxorubicin—thyroid cancer	0.000588	0.0264	CcSEcCtD
Afatinib—ERBB2—saliva-secreting gland—thyroid cancer	0.000567	0.065	CbGeAlD
Afatinib—ERBB4—saliva-secreting gland—thyroid cancer	0.000567	0.065	CbGeAlD
Afatinib—ABCB1—Doxorubicin—thyroid cancer	0.000561	0.00331	CbGbCtD
Afatinib—Mucosal inflammation—Vandetanib—thyroid cancer	0.000531	0.0239	CcSEcCtD
Afatinib—Blood potassium decreased—Sorafenib—thyroid cancer	0.000521	0.0234	CcSEcCtD
Afatinib—Aphthous stomatitis—Sorafenib—thyroid cancer	0.000423	0.019	CcSEcCtD
Afatinib—Interstitial lung disease—Vandetanib—thyroid cancer	0.000415	0.0187	CcSEcCtD
Afatinib—PHKG2—thyroid gland—thyroid cancer	0.000385	0.0441	CbGeAlD
Afatinib—Mucosal inflammation—Sorafenib—thyroid cancer	0.000358	0.0161	CcSEcCtD
Afatinib—EPHA6—head—thyroid cancer	0.000354	0.0406	CbGeAlD
Afatinib—ERBB4—thyroid gland—thyroid cancer	0.000346	0.0396	CbGeAlD
Afatinib—ERBB2—thyroid gland—thyroid cancer	0.000346	0.0396	CbGeAlD
Afatinib—PHKG2—head—thyroid cancer	0.000342	0.0391	CbGeAlD
Afatinib—DYRK1A—thyroid gland—thyroid cancer	0.000333	0.0382	CbGeAlD
Afatinib—LCK—trachea—thyroid cancer	0.000319	0.0366	CbGeAlD
Afatinib—BLK—lymph node—thyroid cancer	0.000314	0.0359	CbGeAlD
Afatinib—ERBB2—head—thyroid cancer	0.000307	0.0352	CbGeAlD
Afatinib—ERBB4—head—thyroid cancer	0.000307	0.0352	CbGeAlD
Afatinib—DYRK1A—head—thyroid cancer	0.000296	0.0339	CbGeAlD
Afatinib—EGFR—thyroid gland—thyroid cancer	0.000294	0.0336	CbGeAlD
Afatinib—Cystitis noninfective—Vandetanib—thyroid cancer	0.000287	0.0129	CcSEcCtD
Afatinib—Cystitis—Vandetanib—thyroid cancer	0.000284	0.0128	CcSEcCtD
Afatinib—Interstitial lung disease—Sorafenib—thyroid cancer	0.00028	0.0126	CcSEcCtD
Afatinib—Dry eye—Vandetanib—thyroid cancer	0.000271	0.0122	CcSEcCtD
Afatinib—Bladder pain—Vandetanib—thyroid cancer	0.000266	0.0119	CcSEcCtD
Afatinib—IRAK1—thyroid gland—thyroid cancer	0.000259	0.0297	CbGeAlD
Afatinib—Sepsis—Vandetanib—thyroid cancer	0.000255	0.0115	CcSEcCtD
Afatinib—LCK—thyroid gland—thyroid cancer	0.000253	0.0289	CbGeAlD
Afatinib—Rhinorrhoea—Sorafenib—thyroid cancer	0.000245	0.011	CcSEcCtD
Afatinib—PHKG2—lymph node—thyroid cancer	0.000239	0.0274	CbGeAlD
Afatinib—ABL1—saliva-secreting gland—thyroid cancer	0.000238	0.0272	CbGeAlD
Afatinib—ERBB2—lymph node—thyroid cancer	0.000215	0.0246	CbGeAlD
Afatinib—DYRK1A—lymph node—thyroid cancer	0.000207	0.0237	CbGeAlD
Afatinib—Dehydration—Vandetanib—thyroid cancer	0.000198	0.00892	CcSEcCtD
Afatinib—Dry skin—Vandetanib—thyroid cancer	0.000195	0.00879	CcSEcCtD
Afatinib—Hypokalaemia—Vandetanib—thyroid cancer	0.000194	0.00873	CcSEcCtD
Afatinib—Nasopharyngitis—Vandetanib—thyroid cancer	0.000191	0.00857	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.000188	0.00846	CcSEcCtD
Afatinib—ABL1—trachea—thyroid cancer	0.000183	0.021	CbGeAlD
Afatinib—EGFR—lymph node—thyroid cancer	0.000182	0.0209	CbGeAlD
Afatinib—Mouth ulceration—Sorafenib—thyroid cancer	0.000179	0.00806	CcSEcCtD
Afatinib—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.000171	0.0077	CcSEcCtD
Afatinib—Weight decreased—Vandetanib—thyroid cancer	0.000167	0.0075	CcSEcCtD
Afatinib—Pneumonia—Vandetanib—thyroid cancer	0.000165	0.00743	CcSEcCtD
Afatinib—Infestation—Vandetanib—thyroid cancer	0.000164	0.00739	CcSEcCtD
Afatinib—Infestation NOS—Vandetanib—thyroid cancer	0.000164	0.00739	CcSEcCtD
Afatinib—Renal failure—Vandetanib—thyroid cancer	0.000162	0.00726	CcSEcCtD
Afatinib—IRAK1—lymph node—thyroid cancer	0.000161	0.0184	CbGeAlD
Afatinib—Stomatitis—Vandetanib—thyroid cancer	0.00016	0.0072	CcSEcCtD
Afatinib—Urinary tract infection—Vandetanib—thyroid cancer	0.00016	0.00718	CcSEcCtD
Afatinib—Conjunctivitis—Vandetanib—thyroid cancer	0.00016	0.00718	CcSEcCtD
Afatinib—LCK—lymph node—thyroid cancer	0.000157	0.018	CbGeAlD
Afatinib—Aphthous stomatitis—Epirubicin—thyroid cancer	0.000156	0.00702	CcSEcCtD
Afatinib—Hepatobiliary disease—Vandetanib—thyroid cancer	0.000155	0.00699	CcSEcCtD
Afatinib—Epistaxis—Vandetanib—thyroid cancer	0.000155	0.00697	CcSEcCtD
Afatinib—ABCG2—saliva-secreting gland—thyroid cancer	0.00015	0.0172	CbGeAlD
Afatinib—Urinary tract disorder—Vandetanib—thyroid cancer	0.000146	0.00655	CcSEcCtD
Afatinib—ABL1—thyroid gland—thyroid cancer	0.000145	0.0166	CbGeAlD
Afatinib—Urethral disorder—Vandetanib—thyroid cancer	0.000145	0.0065	CcSEcCtD
Afatinib—Aphthous stomatitis—Doxorubicin—thyroid cancer	0.000145	0.0065	CcSEcCtD
Afatinib—Eye disorder—Vandetanib—thyroid cancer	0.000138	0.0062	CcSEcCtD
Afatinib—Dehydration—Sorafenib—thyroid cancer	0.000134	0.00601	CcSEcCtD
Afatinib—Mediastinal disorder—Vandetanib—thyroid cancer	0.000133	0.00598	CcSEcCtD
Afatinib—Mucosal inflammation—Epirubicin—thyroid cancer	0.000132	0.00595	CcSEcCtD
Afatinib—Dry skin—Sorafenib—thyroid cancer	0.000132	0.00593	CcSEcCtD
Afatinib—Hypokalaemia—Sorafenib—thyroid cancer	0.000131	0.00589	CcSEcCtD
Afatinib—Alopecia—Vandetanib—thyroid cancer	0.00013	0.00586	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.00013	0.00582	CcSEcCtD
Afatinib—Mental disorder—Vandetanib—thyroid cancer	0.000129	0.00581	CcSEcCtD
Afatinib—ABL1—head—thyroid cancer	0.000129	0.0147	CbGeAlD
Afatinib—Nasopharyngitis—Sorafenib—thyroid cancer	0.000129	0.00578	CcSEcCtD
Afatinib—Malnutrition—Vandetanib—thyroid cancer	0.000128	0.00577	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.000127	0.0057	CcSEcCtD
Afatinib—Dysgeusia—Vandetanib—thyroid cancer	0.000126	0.00565	CcSEcCtD
Afatinib—Muscle spasms—Vandetanib—thyroid cancer	0.000123	0.00555	CcSEcCtD
Afatinib—Mucosal inflammation—Doxorubicin—thyroid cancer	0.000122	0.0055	CcSEcCtD
Afatinib—Keratitis—Epirubicin—thyroid cancer	0.000113	0.00508	CcSEcCtD
Afatinib—Weight decreased—Sorafenib—thyroid cancer	0.000112	0.00506	CcSEcCtD
Afatinib—Cough—Vandetanib—thyroid cancer	0.000112	0.00504	CcSEcCtD
Afatinib—Pneumonia—Sorafenib—thyroid cancer	0.000111	0.00501	CcSEcCtD
Afatinib—Infestation—Sorafenib—thyroid cancer	0.000111	0.00498	CcSEcCtD
Afatinib—Infestation NOS—Sorafenib—thyroid cancer	0.000111	0.00498	CcSEcCtD
Afatinib—Renal failure—Sorafenib—thyroid cancer	0.000109	0.0049	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.000109	0.00488	CcSEcCtD
Afatinib—Stomatitis—Sorafenib—thyroid cancer	0.000108	0.00486	CcSEcCtD
Afatinib—Hepatobiliary disease—Sorafenib—thyroid cancer	0.000105	0.00471	CcSEcCtD
Afatinib—Epistaxis—Sorafenib—thyroid cancer	0.000105	0.0047	CcSEcCtD
Afatinib—Keratitis—Doxorubicin—thyroid cancer	0.000104	0.0047	CcSEcCtD
Afatinib—Infection—Vandetanib—thyroid cancer	0.000104	0.00468	CcSEcCtD
Afatinib—Nervous system disorder—Vandetanib—thyroid cancer	0.000103	0.00462	CcSEcCtD
Afatinib—Skin disorder—Vandetanib—thyroid cancer	0.000102	0.00458	CcSEcCtD
Afatinib—Urinary tract disorder—Sorafenib—thyroid cancer	9.83e-05	0.00442	CcSEcCtD
Afatinib—Connective tissue disorder—Sorafenib—thyroid cancer	9.78e-05	0.0044	CcSEcCtD
Afatinib—Urethral disorder—Sorafenib—thyroid cancer	9.75e-05	0.00439	CcSEcCtD
Afatinib—Insomnia—Vandetanib—thyroid cancer	9.48e-05	0.00426	CcSEcCtD
Afatinib—Dyspnoea—Vandetanib—thyroid cancer	9.34e-05	0.0042	CcSEcCtD
Afatinib—Dyspepsia—Vandetanib—thyroid cancer	9.23e-05	0.00415	CcSEcCtD
Afatinib—ABCG2—thyroid gland—thyroid cancer	9.15e-05	0.0105	CbGeAlD
Afatinib—Decreased appetite—Vandetanib—thyroid cancer	9.11e-05	0.0041	CcSEcCtD
Afatinib—Gastrointestinal disorder—Vandetanib—thyroid cancer	9.05e-05	0.00407	CcSEcCtD
Afatinib—Fatigue—Vandetanib—thyroid cancer	9.04e-05	0.00406	CcSEcCtD
Afatinib—ABL1—lymph node—thyroid cancer	9.01e-05	0.0103	CbGeAlD
Afatinib—Mediastinal disorder—Sorafenib—thyroid cancer	8.97e-05	0.00403	CcSEcCtD
Afatinib—Constipation—Vandetanib—thyroid cancer	8.96e-05	0.00403	CcSEcCtD
Afatinib—Alopecia—Sorafenib—thyroid cancer	8.79e-05	0.00395	CcSEcCtD
Afatinib—Mental disorder—Sorafenib—thyroid cancer	8.72e-05	0.00392	CcSEcCtD
Afatinib—Malnutrition—Sorafenib—thyroid cancer	8.66e-05	0.0039	CcSEcCtD
Afatinib—Dysgeusia—Sorafenib—thyroid cancer	8.48e-05	0.00381	CcSEcCtD
Afatinib—Muscle spasms—Sorafenib—thyroid cancer	8.33e-05	0.00374	CcSEcCtD
Afatinib—Body temperature increased—Vandetanib—thyroid cancer	8.28e-05	0.00373	CcSEcCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—thyroid cancer	8.24e-05	0.0946	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Epirubicin—thyroid cancer	8.24e-05	0.0946	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—thyroid cancer	8.24e-05	0.0946	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—thyroid cancer	7.62e-05	0.0875	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—thyroid cancer	7.62e-05	0.0875	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—thyroid cancer	7.62e-05	0.0875	CbGdCrCtD
Afatinib—Cough—Sorafenib—thyroid cancer	7.56e-05	0.0034	CcSEcCtD
Afatinib—Asthenia—Vandetanib—thyroid cancer	7.52e-05	0.00338	CcSEcCtD
Afatinib—Pruritus—Vandetanib—thyroid cancer	7.41e-05	0.00333	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	7.32e-05	0.00329	CcSEcCtD
Afatinib—Diarrhoea—Vandetanib—thyroid cancer	7.17e-05	0.00322	CcSEcCtD
Afatinib—Cystitis noninfective—Epirubicin—thyroid cancer	7.15e-05	0.00322	CcSEcCtD
Afatinib—Cystitis—Epirubicin—thyroid cancer	7.07e-05	0.00318	CcSEcCtD
Afatinib—Infection—Sorafenib—thyroid cancer	7.02e-05	0.00316	CcSEcCtD
Afatinib—Nervous system disorder—Sorafenib—thyroid cancer	6.93e-05	0.00312	CcSEcCtD
Afatinib—Dizziness—Vandetanib—thyroid cancer	6.93e-05	0.00312	CcSEcCtD
Afatinib—Skin disorder—Sorafenib—thyroid cancer	6.87e-05	0.00309	CcSEcCtD
Afatinib—Dry eye—Epirubicin—thyroid cancer	6.76e-05	0.00304	CcSEcCtD
Afatinib—Vomiting—Vandetanib—thyroid cancer	6.66e-05	0.003	CcSEcCtD
Afatinib—Bladder pain—Epirubicin—thyroid cancer	6.62e-05	0.00298	CcSEcCtD
Afatinib—Mouth ulceration—Epirubicin—thyroid cancer	6.62e-05	0.00298	CcSEcCtD
Afatinib—Cystitis noninfective—Doxorubicin—thyroid cancer	6.62e-05	0.00298	CcSEcCtD
Afatinib—Rash—Vandetanib—thyroid cancer	6.61e-05	0.00297	CcSEcCtD
Afatinib—Dermatitis—Vandetanib—thyroid cancer	6.6e-05	0.00297	CcSEcCtD
Afatinib—Headache—Vandetanib—thyroid cancer	6.57e-05	0.00295	CcSEcCtD
Afatinib—Cystitis—Doxorubicin—thyroid cancer	6.54e-05	0.00294	CcSEcCtD
Afatinib—Sepsis—Epirubicin—thyroid cancer	6.35e-05	0.00286	CcSEcCtD
Afatinib—ERBB2—Doxorubicin—Epirubicin—thyroid cancer	6.34e-05	0.0728	CbGdCrCtD
Afatinib—Dyspnoea—Sorafenib—thyroid cancer	6.3e-05	0.00283	CcSEcCtD
Afatinib—Dry eye—Doxorubicin—thyroid cancer	6.26e-05	0.00281	CcSEcCtD
Afatinib—Nausea—Vandetanib—thyroid cancer	6.23e-05	0.0028	CcSEcCtD
Afatinib—Dyspepsia—Sorafenib—thyroid cancer	6.22e-05	0.0028	CcSEcCtD
Afatinib—Decreased appetite—Sorafenib—thyroid cancer	6.15e-05	0.00276	CcSEcCtD
Afatinib—Bladder pain—Doxorubicin—thyroid cancer	6.13e-05	0.00275	CcSEcCtD
Afatinib—Mouth ulceration—Doxorubicin—thyroid cancer	6.13e-05	0.00275	CcSEcCtD
Afatinib—Gastrointestinal disorder—Sorafenib—thyroid cancer	6.1e-05	0.00274	CcSEcCtD
Afatinib—Fatigue—Sorafenib—thyroid cancer	6.1e-05	0.00274	CcSEcCtD
Afatinib—Constipation—Sorafenib—thyroid cancer	6.05e-05	0.00272	CcSEcCtD
Afatinib—Sepsis—Doxorubicin—thyroid cancer	5.88e-05	0.00264	CcSEcCtD
Afatinib—ERBB2—Epirubicin—Doxorubicin—thyroid cancer	5.87e-05	0.0673	CbGdCrCtD
Afatinib—ABCB1—trachea—thyroid cancer	5.7e-05	0.00653	CbGeAlD
Afatinib—ABCG2—lymph node—thyroid cancer	5.68e-05	0.00651	CbGeAlD
Afatinib—Body temperature increased—Sorafenib—thyroid cancer	5.59e-05	0.00251	CcSEcCtD
Afatinib—Renal impairment—Epirubicin—thyroid cancer	5.59e-05	0.00251	CcSEcCtD
Afatinib—Renal impairment—Doxorubicin—thyroid cancer	5.17e-05	0.00232	CcSEcCtD
Afatinib—Asthenia—Sorafenib—thyroid cancer	5.07e-05	0.00228	CcSEcCtD
Afatinib—Pruritus—Sorafenib—thyroid cancer	5e-05	0.00225	CcSEcCtD
Afatinib—Dehydration—Epirubicin—thyroid cancer	4.94e-05	0.00222	CcSEcCtD
Afatinib—Dry skin—Epirubicin—thyroid cancer	4.87e-05	0.00219	CcSEcCtD
Afatinib—Hypokalaemia—Epirubicin—thyroid cancer	4.84e-05	0.00218	CcSEcCtD
Afatinib—Diarrhoea—Sorafenib—thyroid cancer	4.84e-05	0.00218	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	4.79e-05	0.00215	CcSEcCtD
Afatinib—Nasopharyngitis—Epirubicin—thyroid cancer	4.75e-05	0.00214	CcSEcCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—thyroid cancer	4.73e-05	0.0543	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Epirubicin—thyroid cancer	4.73e-05	0.0543	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Epirubicin—thyroid cancer	4.73e-05	0.0543	CbGdCrCtD
Afatinib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	4.69e-05	0.00211	CcSEcCtD
Afatinib—Dizziness—Sorafenib—thyroid cancer	4.67e-05	0.0021	CcSEcCtD
Afatinib—Dehydration—Doxorubicin—thyroid cancer	4.57e-05	0.00206	CcSEcCtD
Afatinib—ABCB1—thyroid gland—thyroid cancer	4.51e-05	0.00517	CbGeAlD
Afatinib—Dry skin—Doxorubicin—thyroid cancer	4.51e-05	0.00203	CcSEcCtD
Afatinib—Vomiting—Sorafenib—thyroid cancer	4.49e-05	0.00202	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—thyroid cancer	4.48e-05	0.00201	CcSEcCtD
Afatinib—Rash—Sorafenib—thyroid cancer	4.46e-05	0.002	CcSEcCtD
Afatinib—Dermatitis—Sorafenib—thyroid cancer	4.45e-05	0.002	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	4.43e-05	0.00199	CcSEcCtD
Afatinib—Headache—Sorafenib—thyroid cancer	4.43e-05	0.00199	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—thyroid cancer	4.4e-05	0.00198	CcSEcCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—thyroid cancer	4.38e-05	0.0503	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—thyroid cancer	4.38e-05	0.0503	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—thyroid cancer	4.38e-05	0.0503	CbGdCrCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	4.34e-05	0.00195	CcSEcCtD
Afatinib—Upper respiratory tract infection—Epirubicin—thyroid cancer	4.27e-05	0.00192	CcSEcCtD
Afatinib—Nausea—Sorafenib—thyroid cancer	4.2e-05	0.00189	CcSEcCtD
Afatinib—Weight decreased—Epirubicin—thyroid cancer	4.16e-05	0.00187	CcSEcCtD
Afatinib—Pneumonia—Epirubicin—thyroid cancer	4.12e-05	0.00185	CcSEcCtD
Afatinib—Infestation NOS—Epirubicin—thyroid cancer	4.1e-05	0.00184	CcSEcCtD
Afatinib—Infestation—Epirubicin—thyroid cancer	4.1e-05	0.00184	CcSEcCtD
Afatinib—Renal failure—Epirubicin—thyroid cancer	4.03e-05	0.00181	CcSEcCtD
Afatinib—ABCB1—head—thyroid cancer	4e-05	0.00458	CbGeAlD
Afatinib—Stomatitis—Epirubicin—thyroid cancer	3.99e-05	0.0018	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—thyroid cancer	3.98e-05	0.00179	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—thyroid cancer	3.98e-05	0.00179	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—thyroid cancer	3.95e-05	0.00178	CcSEcCtD
Afatinib—Hepatobiliary disease—Epirubicin—thyroid cancer	3.87e-05	0.00174	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—thyroid cancer	3.86e-05	0.00174	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—thyroid cancer	3.85e-05	0.00173	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—thyroid cancer	3.81e-05	0.00171	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—thyroid cancer	3.79e-05	0.0017	CcSEcCtD
Afatinib—Infestation—Doxorubicin—thyroid cancer	3.79e-05	0.0017	CcSEcCtD
Afatinib—Renal failure—Doxorubicin—thyroid cancer	3.73e-05	0.00168	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—thyroid cancer	3.69e-05	0.00166	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—thyroid cancer	3.68e-05	0.00166	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—thyroid cancer	3.68e-05	0.00166	CcSEcCtD
Afatinib—Urinary tract disorder—Epirubicin—thyroid cancer	3.63e-05	0.00163	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—thyroid cancer	3.61e-05	0.00162	CcSEcCtD
Afatinib—Urethral disorder—Epirubicin—thyroid cancer	3.6e-05	0.00162	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—thyroid cancer	3.58e-05	0.00161	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—thyroid cancer	3.58e-05	0.00161	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—thyroid cancer	3.44e-05	0.00155	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—thyroid cancer	3.36e-05	0.00151	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—thyroid cancer	3.34e-05	0.0015	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—thyroid cancer	3.34e-05	0.0015	CcSEcCtD
Afatinib—Mediastinal disorder—Epirubicin—thyroid cancer	3.31e-05	0.00149	CcSEcCtD
Afatinib—Alopecia—Epirubicin—thyroid cancer	3.25e-05	0.00146	CcSEcCtD
Afatinib—Mental disorder—Epirubicin—thyroid cancer	3.22e-05	0.00145	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—thyroid cancer	3.2e-05	0.00144	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—thyroid cancer	3.18e-05	0.00143	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—thyroid cancer	3.13e-05	0.00141	CcSEcCtD
Afatinib—Back pain—Epirubicin—thyroid cancer	3.1e-05	0.00139	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—thyroid cancer	3.08e-05	0.00138	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—thyroid cancer	3.07e-05	0.00138	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—thyroid cancer	3.01e-05	0.00135	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—thyroid cancer	2.98e-05	0.00134	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—thyroid cancer	2.96e-05	0.00133	CcSEcCtD
Afatinib—Dysgeusia—Doxorubicin—thyroid cancer	2.9e-05	0.0013	CcSEcCtD
Afatinib—Back pain—Doxorubicin—thyroid cancer	2.87e-05	0.00129	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—thyroid cancer	2.85e-05	0.00128	CcSEcCtD
Afatinib—ABCB1—lymph node—thyroid cancer	2.8e-05	0.00321	CbGeAlD
Afatinib—Cough—Epirubicin—thyroid cancer	2.79e-05	0.00126	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	2.71e-05	0.00122	CcSEcCtD
Afatinib—Infection—Epirubicin—thyroid cancer	2.6e-05	0.00117	CcSEcCtD
Afatinib—Cough—Doxorubicin—thyroid cancer	2.58e-05	0.00116	CcSEcCtD
Afatinib—Nervous system disorder—Epirubicin—thyroid cancer	2.56e-05	0.00115	CcSEcCtD
Afatinib—Skin disorder—Epirubicin—thyroid cancer	2.54e-05	0.00114	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	2.5e-05	0.00113	CcSEcCtD
Afatinib—Infection—Doxorubicin—thyroid cancer	2.4e-05	0.00108	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—thyroid cancer	2.37e-05	0.00107	CcSEcCtD
Afatinib—Insomnia—Epirubicin—thyroid cancer	2.36e-05	0.00106	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—thyroid cancer	2.35e-05	0.00106	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—thyroid cancer	2.33e-05	0.00105	CcSEcCtD
Afatinib—Dyspepsia—Epirubicin—thyroid cancer	2.3e-05	0.00103	CcSEcCtD
Afatinib—Decreased appetite—Epirubicin—thyroid cancer	2.27e-05	0.00102	CcSEcCtD
Afatinib—Gastrointestinal disorder—Epirubicin—thyroid cancer	2.26e-05	0.00101	CcSEcCtD
Afatinib—Fatigue—Epirubicin—thyroid cancer	2.25e-05	0.00101	CcSEcCtD
Afatinib—Constipation—Epirubicin—thyroid cancer	2.23e-05	0.001	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—thyroid cancer	2.19e-05	0.000983	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—thyroid cancer	2.16e-05	0.000969	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—thyroid cancer	2.13e-05	0.000957	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—thyroid cancer	2.1e-05	0.000945	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	2.09e-05	0.000938	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—thyroid cancer	2.08e-05	0.000937	CcSEcCtD
Afatinib—Constipation—Doxorubicin—thyroid cancer	2.07e-05	0.00093	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—thyroid cancer	2.07e-05	0.000929	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—thyroid cancer	1.91e-05	0.000859	CcSEcCtD
Afatinib—Asthenia—Epirubicin—thyroid cancer	1.87e-05	0.000843	CcSEcCtD
Afatinib—Pruritus—Epirubicin—thyroid cancer	1.85e-05	0.000831	CcSEcCtD
Afatinib—Diarrhoea—Epirubicin—thyroid cancer	1.79e-05	0.000804	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—thyroid cancer	1.73e-05	0.00078	CcSEcCtD
Afatinib—Dizziness—Epirubicin—thyroid cancer	1.73e-05	0.000777	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—thyroid cancer	1.71e-05	0.000769	CcSEcCtD
Afatinib—Vomiting—Epirubicin—thyroid cancer	1.66e-05	0.000747	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—thyroid cancer	1.65e-05	0.000744	CcSEcCtD
Afatinib—Rash—Epirubicin—thyroid cancer	1.65e-05	0.000741	CcSEcCtD
Afatinib—Dermatitis—Epirubicin—thyroid cancer	1.65e-05	0.00074	CcSEcCtD
Afatinib—Headache—Epirubicin—thyroid cancer	1.64e-05	0.000736	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—thyroid cancer	1.6e-05	0.000719	CcSEcCtD
Afatinib—Nausea—Epirubicin—thyroid cancer	1.55e-05	0.000698	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—thyroid cancer	1.54e-05	0.000691	CcSEcCtD
Afatinib—Rash—Doxorubicin—thyroid cancer	1.52e-05	0.000685	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—thyroid cancer	1.52e-05	0.000685	CcSEcCtD
Afatinib—Headache—Doxorubicin—thyroid cancer	1.51e-05	0.000681	CcSEcCtD
Afatinib—Nausea—Doxorubicin—thyroid cancer	1.44e-05	0.000646	CcSEcCtD
Afatinib—EGFR—Axon guidance—NRAS—thyroid cancer	3.51e-06	0.000133	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—AKT1—thyroid cancer	3.48e-06	0.000132	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	3.47e-06	0.000131	CbGpPWpGaD
Afatinib—EGFR—Focal Adhesion—AKT1—thyroid cancer	3.47e-06	0.000131	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDK1—thyroid cancer	3.47e-06	0.000131	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—AKT1—thyroid cancer	3.46e-06	0.000131	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TERT—thyroid cancer	3.46e-06	0.000131	CbGpPWpGaD
Afatinib—LCK—Immune System—CDK1—thyroid cancer	3.46e-06	0.000131	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	3.46e-06	0.000131	CbGpPWpGaD
Afatinib—EGFR—Immune System—IFNA2—thyroid cancer	3.45e-06	0.000131	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TSHR—thyroid cancer	3.42e-06	0.000129	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TERT—thyroid cancer	3.41e-06	0.000129	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—AKT1—thyroid cancer	3.4e-06	0.000129	CbGpPWpGaD
Afatinib—ABL1—Immune System—NRG1—thyroid cancer	3.37e-06	0.000127	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PRKAR1A—thyroid cancer	3.37e-06	0.000127	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—HRAS—thyroid cancer	3.34e-06	0.000126	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—AKT1—thyroid cancer	3.34e-06	0.000126	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—KRAS—thyroid cancer	3.33e-06	0.000126	CbGpPWpGaD
Afatinib—LCK—Immune System—IFNA2—thyroid cancer	3.33e-06	0.000126	CbGpPWpGaD
Afatinib—EGFR—Disease—CDK1—thyroid cancer	3.31e-06	0.000125	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HIF1A—thyroid cancer	3.31e-06	0.000125	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—NRAS—thyroid cancer	3.3e-06	0.000125	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.3e-06	0.000125	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TSHR—thyroid cancer	3.3e-06	0.000125	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—HRAS—thyroid cancer	3.29e-06	0.000125	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—AKT1—thyroid cancer	3.28e-06	0.000124	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—KRAS—thyroid cancer	3.27e-06	0.000124	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HIF1A—thyroid cancer	3.26e-06	0.000123	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	3.25e-06	0.000123	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PRKAR1A—thyroid cancer	3.25e-06	0.000123	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MEN1—thyroid cancer	3.22e-06	0.000122	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—KRAS—thyroid cancer	3.21e-06	0.000122	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—HRAS—thyroid cancer	3.21e-06	0.000121	CbGpPWpGaD
Afatinib—PHKG2—Disease—AKT1—thyroid cancer	3.2e-06	0.000121	CbGpPWpGaD
Afatinib—LCK—Disease—CDK1—thyroid cancer	3.19e-06	0.000121	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HRAS—thyroid cancer	3.16e-06	0.00012	CbGpPWpGaD
Afatinib—ERBB2—Disease—PTGS2—thyroid cancer	3.16e-06	0.000119	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	3.14e-06	0.000119	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	3.14e-06	0.000119	CbGpPWpGaD
Afatinib—ERBB4—Disease—PTGS2—thyroid cancer	3.11e-06	0.000118	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MEN1—thyroid cancer	3.1e-06	0.000117	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HRAS—thyroid cancer	3.04e-06	0.000115	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	3.03e-06	0.000115	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—KRAS—thyroid cancer	3.02e-06	0.000114	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—HRAS—thyroid cancer	3e-06	0.000114	CbGpPWpGaD
Afatinib—ERBB2—Immune System—PTEN—thyroid cancer	2.98e-06	0.000113	CbGpPWpGaD
Afatinib—LCK—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	2.96e-06	0.000112	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—AKT1—thyroid cancer	2.95e-06	0.000112	CbGpPWpGaD
Afatinib—ERBB4—Immune System—PTEN—thyroid cancer	2.94e-06	0.000111	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—NRAS—thyroid cancer	2.93e-06	0.000111	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTCH1—thyroid cancer	2.91e-06	0.00011	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—AKT1—thyroid cancer	2.91e-06	0.00011	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—PTEN—thyroid cancer	2.9e-06	0.00011	CbGpPWpGaD
Afatinib—EGFR—Immune System—NRG1—thyroid cancer	2.88e-06	0.000109	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—NRAS—thyroid cancer	2.87e-06	0.000109	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—SLC5A5—thyroid cancer	2.86e-06	0.000108	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—KRAS—thyroid cancer	2.84e-06	0.000108	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—AKT1—thyroid cancer	2.83e-06	0.000107	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—HRAS—thyroid cancer	2.83e-06	0.000107	CbGpPWpGaD
Afatinib—BLK—Immune System—PTEN—thyroid cancer	2.83e-06	0.000107	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTCH1—thyroid cancer	2.8e-06	0.000106	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—AKT1—thyroid cancer	2.79e-06	0.000106	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NRG1—thyroid cancer	2.78e-06	0.000105	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HRAS—thyroid cancer	2.78e-06	0.000105	CbGpPWpGaD
Afatinib—LCK—Immune System—NRG1—thyroid cancer	2.78e-06	0.000105	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.77e-06	0.000105	CbGpPWpGaD
Afatinib—ERBB2—Disease—PTEN—thyroid cancer	2.75e-06	0.000104	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—BRAF—thyroid cancer	2.74e-06	0.000104	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—HRAS—thyroid cancer	2.73e-06	0.000103	CbGpPWpGaD
Afatinib—ERBB4—Disease—PTEN—thyroid cancer	2.71e-06	0.000103	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—BRAF—thyroid cancer	2.7e-06	0.000102	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—AKT1—thyroid cancer	2.69e-06	0.000102	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—AKT1—thyroid cancer	2.68e-06	0.000101	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SST—thyroid cancer	2.66e-06	0.000101	CbGpPWpGaD
Afatinib—ERBB2—Immune System—NRAS—thyroid cancer	2.66e-06	0.000101	CbGpPWpGaD
Afatinib—EGFR—Disease—NRG1—thyroid cancer	2.66e-06	0.000101	CbGpPWpGaD
Afatinib—ERBB4—Immune System—NRAS—thyroid cancer	2.62e-06	9.92e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—NRAS—thyroid cancer	2.59e-06	9.78e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SST—thyroid cancer	2.57e-06	9.7e-05	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—HRAS—thyroid cancer	2.56e-06	9.7e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CALCA—thyroid cancer	2.56e-06	9.69e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NRG1—thyroid cancer	2.56e-06	9.69e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—NRAS—thyroid cancer	2.52e-06	9.54e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—KRAS—thyroid cancer	2.52e-06	9.53e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—AKT1—thyroid cancer	2.5e-06	9.47e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—NRAS—thyroid cancer	2.5e-06	9.46e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TERT—thyroid cancer	2.5e-06	9.46e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—PTEN—thyroid cancer	2.48e-06	9.37e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—KRAS—thyroid cancer	2.47e-06	9.35e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CALCA—thyroid cancer	2.47e-06	9.34e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—NRAS—thyroid cancer	2.46e-06	9.3e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—NRAS—thyroid cancer	2.42e-06	9.16e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HRAS—thyroid cancer	2.42e-06	9.14e-05	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—AKT1—thyroid cancer	2.41e-06	9.12e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—RXRA—thyroid cancer	2.4e-06	9.09e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HIF1A—thyroid cancer	2.39e-06	9.04e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TERT—thyroid cancer	2.39e-06	9.03e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PTEN—thyroid cancer	2.39e-06	9.03e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PTEN—thyroid cancer	2.38e-06	9e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—NRAS—thyroid cancer	2.37e-06	8.95e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.32e-06	8.79e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDK1—thyroid cancer	2.32e-06	8.77e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TERT—thyroid cancer	2.3e-06	8.7e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PTEN—thyroid cancer	2.29e-06	8.67e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—KRAS—thyroid cancer	2.29e-06	8.67e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HIF1A—thyroid cancer	2.28e-06	8.64e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—KRAS—thyroid cancer	2.26e-06	8.54e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDK1—thyroid cancer	2.24e-06	8.46e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—KRAS—thyroid cancer	2.23e-06	8.42e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—NRAS—thyroid cancer	2.21e-06	8.36e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HIF1A—thyroid cancer	2.2e-06	8.32e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—thyroid cancer	2.2e-06	8.31e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—KRAS—thyroid cancer	2.17e-06	8.21e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PTEN—thyroid cancer	2.16e-06	8.16e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—KRAS—thyroid cancer	2.15e-06	8.14e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—HRAS—thyroid cancer	2.14e-06	8.1e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—AKT1—thyroid cancer	2.13e-06	8.07e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—NRAS—thyroid cancer	2.13e-06	8.05e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—NRAS—thyroid cancer	2.12e-06	8.03e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—KRAS—thyroid cancer	2.12e-06	8e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—HRAS—thyroid cancer	2.1e-06	7.95e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—KRAS—thyroid cancer	2.08e-06	7.88e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TPR—thyroid cancer	2.07e-06	7.82e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.07e-06	7.81e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—NRAS—thyroid cancer	2.04e-06	7.73e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—KRAS—thyroid cancer	2.04e-06	7.7e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PRKAR1A—thyroid cancer	2.03e-06	7.69e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCND1—thyroid cancer	2e-06	7.56e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—BRAF—thyroid cancer	1.98e-06	7.49e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCND1—thyroid cancer	1.97e-06	7.45e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HRAS—thyroid cancer	1.95e-06	7.37e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PTEN—thyroid cancer	1.93e-06	7.3e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—NRAS—thyroid cancer	1.92e-06	7.28e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HRAS—thyroid cancer	1.92e-06	7.26e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KRAS—thyroid cancer	1.9e-06	7.19e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PTEN—thyroid cancer	1.9e-06	7.19e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HRAS—thyroid cancer	1.89e-06	7.16e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—AKT1—thyroid cancer	1.89e-06	7.15e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—BRAF—thyroid cancer	1.89e-06	7.15e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NRG1—thyroid cancer	1.86e-06	7.04e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—AKT1—thyroid cancer	1.86e-06	7.02e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—HRAS—thyroid cancer	1.85e-06	6.98e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KRAS—thyroid cancer	1.83e-06	6.93e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—HRAS—thyroid cancer	1.83e-06	6.92e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KRAS—thyroid cancer	1.83e-06	6.91e-05	CbGpPWpGaD
Afatinib—LCK—Disease—BRAF—thyroid cancer	1.82e-06	6.89e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—thyroid cancer	1.81e-06	6.84e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—HRAS—thyroid cancer	1.8e-06	6.8e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NRG1—thyroid cancer	1.79e-06	6.79e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—HRAS—thyroid cancer	1.77e-06	6.7e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KRAS—thyroid cancer	1.76e-06	6.66e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.74e-06	6.6e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—thyroid cancer	1.73e-06	6.54e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NRAS—thyroid cancer	1.72e-06	6.51e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—AKT1—thyroid cancer	1.72e-06	6.5e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NRAS—thyroid cancer	1.7e-06	6.41e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—AKT1—thyroid cancer	1.69e-06	6.41e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PTEN—thyroid cancer	1.69e-06	6.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TERT—thyroid cancer	1.67e-06	6.32e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—AKT1—thyroid cancer	1.67e-06	6.32e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KRAS—thyroid cancer	1.66e-06	6.27e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—AKT1—thyroid cancer	1.63e-06	6.16e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—thyroid cancer	1.62e-06	6.11e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—AKT1—thyroid cancer	1.62e-06	6.11e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TERT—thyroid cancer	1.61e-06	6.09e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HIF1A—thyroid cancer	1.6e-06	6.05e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—thyroid cancer	1.59e-06	6.01e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—thyroid cancer	1.56e-06	5.92e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—thyroid cancer	1.56e-06	5.89e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—thyroid cancer	1.55e-06	5.87e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.55e-06	5.85e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HIF1A—thyroid cancer	1.54e-06	5.83e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—thyroid cancer	1.53e-06	5.78e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—thyroid cancer	1.53e-06	5.78e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARG—thyroid cancer	1.52e-06	5.74e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NRAS—thyroid cancer	1.51e-06	5.7e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—thyroid cancer	1.5e-06	5.66e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—thyroid cancer	1.48e-06	5.6e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—thyroid cancer	1.47e-06	5.57e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—thyroid cancer	1.46e-06	5.52e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—thyroid cancer	1.44e-06	5.47e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTEN—thyroid cancer	1.44e-06	5.46e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—thyroid cancer	1.43e-06	5.4e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—NRAS—thyroid cancer	1.41e-06	5.33e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—thyroid cancer	1.41e-06	5.33e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTEN—thyroid cancer	1.39e-06	5.28e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PTEN—thyroid cancer	1.39e-06	5.26e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—thyroid cancer	1.38e-06	5.2e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—thyroid cancer	1.37e-06	5.18e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTEN—thyroid cancer	1.33e-06	5.04e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BRAF—thyroid cancer	1.32e-06	5.01e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—thyroid cancer	1.32e-06	5e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—thyroid cancer	1.32e-06	4.98e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—RXRA—thyroid cancer	1.3e-06	4.92e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—thyroid cancer	1.3e-06	4.91e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—thyroid cancer	1.3e-06	4.9e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NRAS—thyroid cancer	1.29e-06	4.87e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTEN—thyroid cancer	1.28e-06	4.85e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BRAF—thyroid cancer	1.28e-06	4.83e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—thyroid cancer	1.26e-06	4.76e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NRAS—thyroid cancer	1.24e-06	4.71e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—thyroid cancer	1.24e-06	4.7e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—thyroid cancer	1.24e-06	4.69e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NRAS—thyroid cancer	1.24e-06	4.69e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—thyroid cancer	1.21e-06	4.59e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—thyroid cancer	1.19e-06	4.52e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NRAS—thyroid cancer	1.19e-06	4.49e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NRAS—thyroid cancer	1.15e-06	4.33e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—thyroid cancer	1.11e-06	4.21e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—thyroid cancer	1.11e-06	4.19e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—thyroid cancer	1.1e-06	4.17e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—thyroid cancer	1.1e-06	4.14e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—thyroid cancer	1.07e-06	4.05e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—thyroid cancer	1.07e-06	4.04e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTEN—thyroid cancer	1.04e-06	3.94e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—thyroid cancer	1.03e-06	3.9e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—thyroid cancer	1.02e-06	3.87e-05	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—thyroid cancer	9.85e-07	3.73e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—thyroid cancer	9.73e-07	3.68e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—thyroid cancer	9.66e-07	3.65e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—thyroid cancer	9.52e-07	3.6e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—thyroid cancer	9.41e-07	3.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTEN—thyroid cancer	9.33e-07	3.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—thyroid cancer	9.31e-07	3.52e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—thyroid cancer	9.1e-07	3.44e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—thyroid cancer	9.1e-07	3.44e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—thyroid cancer	9.07e-07	3.43e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTEN—thyroid cancer	8.99e-07	3.4e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—thyroid cancer	8.69e-07	3.29e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—thyroid cancer	8.38e-07	3.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NRAS—thyroid cancer	8.32e-07	3.15e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—thyroid cancer	8.31e-07	3.14e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARG—thyroid cancer	8.21e-07	3.1e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—thyroid cancer	8.04e-07	3.04e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NRAS—thyroid cancer	8.02e-07	3.03e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—thyroid cancer	8.01e-07	3.03e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—thyroid cancer	7.68e-07	2.9e-05	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—thyroid cancer	7.4e-07	2.8e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—thyroid cancer	7.16e-07	2.71e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—thyroid cancer	6.9e-07	2.61e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—thyroid cancer	6.46e-07	2.44e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—thyroid cancer	6.36e-07	2.41e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—thyroid cancer	6.13e-07	2.32e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—thyroid cancer	6.09e-07	2.3e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—thyroid cancer	6e-07	2.27e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—thyroid cancer	5.87e-07	2.22e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTEN—thyroid cancer	5.63e-07	2.13e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—thyroid cancer	5.37e-07	2.03e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—thyroid cancer	5.18e-07	1.96e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—thyroid cancer	3.24e-07	1.23e-05	CbGpPWpGaD
